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Structure-based drug design: the discovery of novel nonpeptide
orally active inhibitors of human renin
J Rahuel, V Rasetti, J Maibaum, H Rüeger, R Göschke, N-C Cohen*, S Stutz,
F Cumin, W Fuhrer, JM Wood and MG Grütter†
Background: The aspartic proteinase renin plays an important physiological
role in the regulation of blood pressure. It catalyses the first step in the
conversion of angiotensinogen to the hormone angiotensin II. In the past, potent
peptide inhibitors of renin have been developed, but none of these compounds
has made it to the end of clinical trials. Our primary aim was to develop novel
nonpeptide inhibitors. Based on the available structural information concerning
renin–substrate interactions, we synthesized inhibitors in which the peptide
portion was replaced by lipophilic moieties that interact with the large
hydrophobic S1/S3-binding pocket in renin.
Results: Crystal structure analysis of renin–inhibitor complexes combined with
computational methods were employed in the medicinal-chemistry optimisation
process. Structure analysis revealed that the newly designed inhibitors bind as
predicted to the S1/S3 pocket. In addition, however, these compounds interact
with a hitherto unrecognised large, distinct, sub-pocket of the enzyme that
extends from the S3-binding site towards the hydrophobic core of the enzyme.
Binding to this S3sp sub-pocket was essential for high binding affinity. This
unprecedented binding mode guided the drug-design process in which the
mostly hydrophobic interactions within subsite S3sp were optimised.
Conclusions: Our design approach led to compounds with high in vitro affinity
and specificity for renin, favourable bioavailability and excellent oral efficacy in
lowering blood pressure in primates. These renin inhibitors are therefore
potential therapeutic agents for the treatment of hypertension and related
cardiovascular diseases.
Introduction
The renin–angiotensin system (Figure 1) plays a major role
in regulating cardiovascular and renal function and in main-
taining the electrolyte balance of the body [1–3]. Imbalance
may lead to blood pressure abnormalities such as hyperten-
sion, or to congestive heart failure. Extensive clinical studies
using inhibitors of the angiotensin converting enzyme
(ACE) have shown the importance of the renin–angiotensin
system in blood-pressure regulation [4,5] and led to the
therapeutic application of ACE inhibitors in the treatment
of hypertension and congestive heart failure [5–8]. The
metabolic degradation of bradykinin and other members of
the kinin family by ACE, however, may be responsible for
some of the adverse effects of ACE inhibitors [9]. It is there-
fore desirable to have drugs that influence the formation or
action of angiotensin II at other points in the cascade
[10–12]. To interfere more specifically with the
renin–angiotensin cascade, antagonists of the angiotensin II
receptor were developed and introduced to the market [13].
Due to its high specificity for only one substrate, namely
angiotensinogen, renin was also identified as an ideal target
for antihypertensive drugs. Potent and selective inhibitors
of renin could therefore provide a new alternative therapy
for the treatment of hypertension without side effects.
Renin (EC 3.4.99.19) is a member of the well-studied
family of aspartic proteinases [14,15]. Renin controls the
first and rate-limiting step of the renin–angiotensin system
catalysing the cleavage of the Leu10–Val11 peptide bond of
angiotensinogen and releasing the decapeptide angiotensin
I (Figure 1). Angiotensinogen is the only known physiologi-
cal substrate for renin; therefore renin is an absolutely
essential and extremely specific enzyme, in contrast to the
angiotensin-converting enzyme (ACE), which can be
bypassed by the serine proteinase chymase and is also
active against other peptides such as bradykinin. A large
variety of peptide inhibitors of human renin with different
stable transition-state analogues of the scissile peptide bond
have been developed. Because none of these compounds
survived all stages of drug development, there was a need
for new classes of nonpeptide renin inhibitors that fulfil all
criteria for becoming successful drugs. Three-dimensional
structures of a number of mammalian and viral aspartic pro-
teinases have been determined. Crystal structures of
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human and mouse renin in complex with peptide and pep-
tidomimetic inhibitors have been reported (reviewed in
[16]; [17–21]). In light of this, we decided to follow a struc-
ture-based approach to design novel nonpeptide inhibitors.
Here we report the basic concept of our approach, as well as
six crystal structures of a selection of the designed
inhibitors bound to human renin. The structural informa-
tion was important for both the validation of the initial
design concept and structure–activity optimisation.
Results and discussion
Inhibitor design concept
Crystal structures of human renin show that the enzyme
consists of two mainly β-sheet domains related by an
approximately twofold axis (Figure 2a). The active-site
cleft is located between the two domains and extends over
eight residues of the respective substrate. Each domain
provides one of the catalytically essential aspartic acid car-
boxylates (Asp32 and Asp215; residue numbers in this
article are according to the pepsin sequence). In all previ-
ous peptidic inhibitor–enzyme complexes the inhibitors
bind in an extended conformation occupying the active
site from the S4 to the S2′ subsites (Figure 2).
The initial substrate-based design of inhibitors of renin
provided peptide analogues of the amino-terminal part of
the substrate angiotensinogen, in which the amino acids
flanking the cleavage site were modified [22]. An instru-
mental approach towards the development of nonsubstrate-
based renin inhibitors was the replacement of the scissile
Leu10–Val11 dipeptide moiety according to the transition-
state analogue concept [23,24], which led to a vast number
of in vitro highly potent peptide-like (classified recently as
type-I inhibitors [25]) renin inhibitors. Poor oral absorption
and rapid biliary uptake, resulting from unfavourable
lipophilicity and molecular size, are major reasons for the
limited bioavailability of most peptide-like renin inhibitors.
The renin inhibitor CGP 38′560 (1) [26] as a representa-
tive of such type-I inhibitors contains the dipep-
tide isostere (2S,4S,5S)-5-amino-4-hydroxy-2-isopropyl-6-
cyclohexyl-hexanoic acid at the P1–P1′ position and
mimics the substrate angiotensinogen from residue P3 to
P1′, according to the Schechter and Berger nomenclature
[27]. The compound is a potent and specific inhibitor with
an IC50 value of 0.7 × 10–9 M for human renin [28], but it
has only a weak blood-pressure lowering effect in salt-
depleted marmosets after oral dosing, mainly as a result of
very limited overall bioavailability (Table 1).
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Figure 1
The renin–angiotensin cascade. ACE, angiotensin converting enzyme;
AT II, angiotensin II.
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Figure 2
Structure of renin in complex with the peptidic
inhibitor CGP 38′560 (1). (a) General view of
human renin in complex with the inhibitor 1.
Renin is represented as a blue ribbon and the
inhibitor as sticks with bonds corresponding to
carbon atoms in green. The amino- and
carboxy-terminal domains are at the top and at
the bottom, respectively (figure made using
MOLSCRIPT [49] and Raster3D [50,51]).
(b) Closer view of the active site with 1 in the
same orientation as in (a). The surface of the
enzyme is represented as calculated by the
program GRASP [52]. Part of the ‘flap’
(residues 74–78) as well as residues 110–111,
241–243 and 289 have been removed from
the model, previous to calculation of the protein
surface, to allow visualization of the active site
interior. The inhibitor binds within the active site
of renin occupying the binding pockets S4 to
S2′ in an extended conformation.
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Table 1
Biological activity of selected inhibitors of human renin.
IC50 (µM) IC50 (µM) IC50 (µM)
Compound Formula Purified human renin Plasma human renin Porcine pepsin
1 0.001 0.0007 8.2
2* 0.052 0.043 >100
3 0.0008 0.006 >100
4* 0.0005 0.0004 >100
5* 0.0001 0.0005 >100
6 0.003 0.034 >100
7 0.022 0.026 >100
8 0.0009 0.004 >100
9 0.0004 0.003 >100
10 0.0006 0.0006 >100
For assays used to determine IC50 values, see [26]. *X-ray complex to human renin not determined. 
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Because of our experience with inhibitor 1 and analogues
thereof, the search for nonpeptide inhibitors of lower mol-
ecular weight was initiated to identify compounds with
good oral bioavailability and efficacy in animal models and
stablility against metabolic degradation [29,30]. After
analysing the shape and chemical properties of the active
site of human renin initially using a homology model struc-
ture [31], it became apparent that the S1 and S3 pockets
form a contiguous and large hydrophobic cavity [30,32].
Applying molecular modelling methods, compounds were
designed that would optimally exploit the extended
hydrophobic surface corresponding to the large S3–S1
cavity (Figure 2b) and therefore might lead to a sufficient
increase in free binding energy through improved van der
Waals contacts. At the same time this would allow the
elimination of the peptide mainchain from P1 to P4
leading to the nonpeptidic inhibitors as shown in Figure 3.
A similar design rationale for human renin inhibitors has
also been proposed by two other groups [33,34].
All hydroxyethylene transition-state mimetic inhibitors
resulting from this design concept are structurally charac-
terised by a directly linked P1–P3-moiety, and lack the
P1–P4 spanning backbone of peptide inhibitors. Variations
and extensions of the P3 moiety were explored syntheti-
cally and analysed by X-ray crystallography in an iterative
design process after the first observation that the ethyl car-
boxylate group of the P3 heterocycle of inhibitor 3 binds
into a deep narrow and well-defined hydrophobic sub-
pocket which is accessible from the S3 pocket.
Crystal structures of renin complexed with novel
nonpeptide inhibitors 
The crystal structures of six renin inhibitor complexes
have been determined and refined (from this point in the
manuscript, ‘renin’ stands for ‘recombinant glycosylated
human renin’). Inhibitors with different P3–P1 moieties
were chosen (compare with Table 1 for inhibitor struc-
tures). In all structures, the electron density for the
inhibitor allows them to be positioned in the active site of
renin (Figure 4 shows the electron density for inhibitors 6
and 10). Table 2 summarises the corresponding crystallo-
graphic data and refinement statistics. Because structure
determinations for the first five inhibitors were performed
at room temperature, the observed resolution was
between 2.8 and 3.2 Å. The structure of the inhibitor
10–enzyme complex, carried out at 100 K, was determined
at 2.2 Å resolution and is the reference structure for most
of the discussion regarding enzyme–inhibitor interactions
and differences in enzyme conformation in the two inde-
pendent molecules of the asymmetric unit of the cubic
crystal form.
The general fold of renin has already been described in
the presence and in the absence of ligand [18]. In short,
renin has the predominantly β-sheet fold characteristics of
the aspartic protease family. The substrate binding cleft
and active site of the enzyme are formed between the two
structurally similar amino- and carboxy-terminal domains
(Figure 2a). The catalytic residues Asp32 and Asp215 are
located in the centre of the cleft. In the cubic crystal form
there are two independent renin molecules in the asym-
metric unit. One adopts an open and the other a closed
conformation. The two conformations differ in the orien-
tation of the carboxy-terminal loops 198–204, 236–254 and
270–286 [18]. These differences do not influence the
inhibitor–enzyme interactions directly as illustrated by the
comparison of the hydrogen-bond interactions (Table 3).
Analysis of the B-factors for the mainchain of the 2.2 Å
structure with inhibitor 10 revealed that the closed mol-
ecule is more rigid than the open one. The differences
reside mainly in the amino-terminal domains as illustrated
in the plot of temperature factors (Figure 5). 
Binding of small nonpeptide inhibitors
Despite lacking the mainchain P2 to P4, all novel nonpep-
tide inhibitors are positioned within the extended binding
cleft of renin occupying the S3 to S2′ subsites. However,
an altered hydrogen-bonding pattern as well as binding
interactions to a predominantly hydrophobic cavity not
utilised by peptide substrates or inhibitors were observed
(see below). For comparison a superposition of the
inhibitor 10 with the peptide inhibitor CGP 38′560 (1) is
shown in Figure 6a. Tables 3 and 4 summarise the hydro-
gen-bond interactions between the inhibitors and renin,
and the residues of renin forming the binding pockets
occupied by the inhibitors.
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Figure 3
Representation of the P3–P1 structural design approach towards
novel nonpeptide renin inhibitors. 
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Mainchain hydrogen-bond interactions 
The P2′ terminal amide nitrogen of 10 forms a hydrogen
bond with the carbonyl oxygen atom of Arg74 (Table 3).
The terminal carbonyl oxygen of the inhibitor is hydrogen
bonded to a water molecule, which itself forms a network
of hydrogen bonds with the sidechains of Gln128 and
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Figure 4
Stereoviews of Fobs–Fcalc electron-density
maps of the active site of renin in the
complexes with inhibitors (a) 6 and (b) 10.
The electron densities, calculated after
refinement, with the inhibitors omitted, are
contoured at 3σ above the mean density.
Resolutions are 3.1 and 2.2 Å for complexes
containing 6 and 10, respectively.
Table 2
Data collection and refinement statistics of complexes of inhibitors with human renin.
3 6 7 8 9 10
Space group P213 P213 P41212 P213 P213 P213
Crystal cell (Å) a = b = c = 142.9 a = b = c = 143.0 a = b = 98.4 c = 95.6 a = b = c = 142.9 a = b = c = 143.0 a = b = c = 141.6
Resolution (Å) 2.8 3.1 2.9 3.2 3.1 2.2
Observations 59779 57033 38241 43376 59418 187361
Unique 23603 17263 10676 15411 17734 46674
Multiplicity 2.53 3.30 3.58 2.81 3.35 4.01
Completeness (%) 98 96 98 92 99 97
Rsym 0.101 0.119 0.062 0.127 0.118 0.065
Program TNT XPLOR XPLOR XPLOR TNT X-PLOR
Resolution range (Å) 10.0–2.8 10.0–3.1 10.0–2.9 10.0–3.2 10.0–3.1 40.0–2.2
Reflections 23086 17263 10398 15335 17183 46674
R factor 0.214 0.217 0.228 0.236 0.210 0.205
(Rfree = 0.266)
rms bonds (Å) 0.080 0.019 0.022 0.018 0.082 0.011
rms angles (°) 7.019 3.673 3.730 3.57 7.117 2.03
rms dihedral (°) 28.46 27.33 26.60 27.46 28.56 25.87
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Thr295 residues and with another water molecule. The
carboxamide group between P1′ and P2′ forms hydrogen
bonds analogous to substrate or peptide inhibitors
(Table 3, Figure 7). In complexes with peptide inhibitors
the hydroxyl group of the transition state dipeptide
isostere forms hydrogen bonds with both catalytic aspartic
acid residues Asp215 and Asp32 in an almost symmetric
manner. In the structures with the nonpeptide inhibitors,
the primary amino group substituting the P2–P1 amide
group of peptide inhibitors forms hydrogen bonds with
the mainchain carbonyl of Gly217 and the carboxylate of
Asp215 and in the structure with compound 3 with Asp32
498 Chemistry & Biology 2000, Vol 7 No 7
Figure 5
Superposition of temperature factor plots of
the two molecules of renin in the asymmetric
unit of the cubic crystal form in the complex
with inhibitor 10 (resolution 2.2 Å). The blue
and the red curves correspond to the closed
and open forms, respectively. The gap in the
region 160 corresponds to a loop which is
known to be undefined in all structures of
renin described up to now.
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Table 3
Interactions of the inhibitors in the active site of human renin (hydrogen bonds).
Inhibitor moiety Inhibitor Residue and atom of renin Distance (Å)
P2′ terminal nitrogen 10 Arg74 O 3.0–3.2
P2′ nitrogen all Gly34 O 2.8–3.9
P1′ carbonyl all Ser76 N 2.8–3.5
hydroxyl mimic all Asp32 Oδ1, Oδ2 2.5–4.1
Asp215 Oδ1, Oδ2 2.8–4.5
P1 amine 3 Asp32 Oδ1, Oδ2 2.8–4.3
6 Asp215 Oδ1, Oδ2 2.8–4.1
7
8
10
P1 amine all Gly217 O 2.5–4.3
Carbonyl between P3 and P1 3 Thr77 Oγ 2.6–3.7
6
7
8
Carbonyl of the P3 substituent 3 Ser219 N 3.2–3.9
Ser219 Oγ 2.8–3.1
Distal ether of the P3 substituent 7 Tyr14 N 2.8–3.1
8
9
10
Minimal and maximal interatomic distances observed between atoms of hydrophilic moieties of the inhibitors and their potential partner in renin.
Ranges of interatomic distances listed take into account the distances observed for different inhibitors but also the two forms (‘open’ and ‘closed’)
observed for complexes studied in the cubic space group (with the exception of inhibitor 7). 
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(Figure 7, Table 3). In order to form optimal hydrogen-
bond interactions, the NH2 group is shifted towards the
carboxylates of the catalytic residues, and as a conse-
quence the mimetic hydroxyl group is positioned closer to
Asp32 than Asp215. In addition, the χ2 angle of the
Asp215 sidechain is shifted by up to 48° as compared with
the structure with the peptide inhibitor 1, moving the
Asp215 carboxylate further away from the inhibitor
hydroxyl group. Figure 6b illustrates this shift and the for-
mation of a nonsymmetrical hydrogen-bond network of
the OH group to both aspartate residues for inhibitor 3
(see also Table 3). The altered hydrogen-bond pattern for
nonpeptide compared with peptide-like inhibitors may
originate from the electrostatic interaction between the
positively charged amino group and the carboxylates of
the catalytic residues. Ligand-inducible flexibility of the
protein could also facilitate this rearrangement, as could
the strong hydrophobic interactions of the inhibitors
within the S3/S1 binding pocket. As an exception, the
NH2 group of 9 does not form a hydrogen bond to either
of the catalytic aspartates: this can be explained by the
shorter all-carbon skeleton of this inhibitor and the shorter
distance between the NH2-bearing carbon and the phenyl
group of the P3 moiety. This suggests that the strong
hydrophobic interactions to the S1 and S3 pockets, as well
as to the nonsubstrate binding site (see below) play a dom-
inant role with respect to the relative orientation of the
inhibitor along the cleft, in contrast to any potential elec-
trostatic effects induced by the inhibitor amine. In con-
trast, the hydrogen-bonding  pattern for compound 10 is
again similar to that of compound 3 because of a different
P1′, P2′ moiety.
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Figure 6
Structures of nonpeptide inhibitors complexed
with human renin. (a) Superposition of the
inhibitor 10 (purple) and CGP 38′560
(1, green) in the active site of renin.
(b) Superposition of inhibitors 3 and
CGP 38′560 (1), detail in the catalytic site.
1 is green, inhibitor 3 is orange, and the two
catalytic aspartic acid residues are purple.
Arrows point out the relative shift of the P1
nitrogen and hydroxyl oxygen atoms of 3 as
compared with 1. (c) The newly discovered
S3sp subsite accommodating the
corresponding P3sp residues of three different
types of inhibitors superimposed. The active
site is rotated by about 90° following the
horizontal axis compared to (a,b). The view
extends from the catalytic site to the P3sp
subpocket. The sidechain of Ser219 was
removed from the model before surface
calculation. The color codes of the inhibitors
are the following: 3 orange, 6 blue, 8 purple.
Renin residues are labeled. (d) Superposition
of CGP 38′560 (1, green) and inhibitor 10
(enzyme shown only) complexes. In the
absence of a P2–P3 peptide bond, the
His287 sidechain, which forms a water-
mediated hydrogen bond with the P3 carbonyl
in the peptidic complex, is shifted towards
Tyr220 in the presence of 10. Renin in its
complex with 1 is light green, and in the
complex with inhibitor 10 (enzyme shown
only) in light purple. The figure was prepared
using the program GRASP [52].
Table 4
Interactions of the inhibitors in the active site of  human renin
(residues in renin forming the binding pockets).
S3sp S3 S1 S1′ S2′
Gln13 Thr12 Val30 Ser76 Gly34
Tyr14 Gln13 Asp32 Leu213 Ser35
Val30 Pro111 Tyr75 Asp215 Leu73
Val120 Phe112 Thr77 Ile291 Arg74
Tyr155 Leu114 Phe112 Pro292 Tyr75
Gly217 Ala115 Phe117 Thr295 Gln128
Ala218 Phe117 Val120 Thr298 Ile130
Ser219 Ser219 Asp215 Ala300
Ala303 Gly217
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Interactions in the specificity pockets
Like the peptide-based CGP 38′560 (1), compounds 3–9
are substituted by a n-butyl residue at the P2′ carboxy-ter-
minal end. This alkyl chain interacts with hydrophobic
residues of the corresponding S2′ pocket (Table 4). The
S1′ pocket is partially filled by either a methyl or an iso-
propyl group similar to the P1′ isopropyl in previously
published structures [18,20,21]. In all inhibitor structures
the hydrophobic P1 residue occupies the S1 pocket.
Inhibitors bearing a more bulky P1 isopropyl residue (e.g.,
compounds 8 and 9) penetrate more deeply into the S1
pocket. The P1 moiety of the inhibitors together with the
adjacent phenyl spacer as in compound 9 constitutes a
large hydrophobic entity that is smoothly accommodated
by the complementary hydrophobic S1/S3 ‘superpocket’
of the enzyme. The S3 pocket also has a strong preference
for hydrophobic aromatic residues as seen for peptide-like
inhibitors, although this subsite may also accommodate
bulky lipophilic groups [35]. Accordingly, the P3 aryl
group of the nonpeptide inhibitors 3, 6–8 is found at
roughly the same position within the S3 pocket as the P3
phenyl sidechain of CGP 38′560 (1), and as observed in
the complex of polyhydroxymonoamide inhibitors to
human renin [18,20,21]. The orientation of the P3 moiety
in the nonpeptide inhibitors is markedly altered compared
with peptide inhibitors, that is the aryl portion is rotated
about a horizontal axis by ~30–40° towards Phe117 as com-
pared with the P3 phenyl of inhibitor 1 (Figure 6c). In this
orientation the aromatic system fits better to the
hydrophobic surface of the contiguous S3–S1 pocket. The
X-ray structures of complexes with inhibitors 9 and 10
reveal that the polar methoxy group sits in the S3-binding
site, which was expected to bind only bulky hydrophobic
residues. The position of the methyl oxygen atom is
roughly within the plane of the P3 aryl of the other
inhibitors including 1, whereas the methyl is pointing
towards Leu114, Ala115 and Phe117. The phenyl ring of
inhibitors 9 and 10 therefore functions as a hydrophobic
spacer connecting the P3-methoxy residue to the P1 iso-
propyl moiety forms hydrophobic contacts with the
sidechains of residues Phe117 and Pro111 at about 4 Å
(Table 4). In contrast to 9 and 10, all other inhibitors (3–8)
have a polar amide spacer linking the hydrophobic P3 and
P1 residues. The carbonyl group of these functionalised
spacers forms hydrogen bonds with the sidechain of Thr77
of the flap region. This additional hydrogen-bond inter-
action may compensate for the weaker van der Waals
interactions of inhibitors 3, 6 and 7, for which a non-
optimal fit of the hydrophobic moieties in P1 is observed.
Interactions in the subsite S3sp
The most surprising finding was the binding of the novel
nonpeptide inhibitors to a very distinct sub-pocket that
has not been exploited previously as an inhibitor-binding
site (Figure 6a,c). The crystal structures presented here
show that the structurally different substituents of the P3
heterocycle (compare with compounds 3, 4 and 6) or the
P3 spacer phenyl (compare with compounds 7–10) of the
inhibitors all point from the S3 pocket into the same non-
substrate cavity. We named this cavity S3 sub-pocket
(S3sp). S3sp is oriented perpendicular to the axis of the
enzyme cleft and ‘points’ towards the core of the protein.
This channel is about 9 Å deep, corresponding to the
length of a six-carbon aliphatic chain. This pocket has also
been noted by Tong et al. [20]. Substrates or peptide
inhibitors do not bind to this sub-pocket as revealed by
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Hydrogen-bonding networks of renin bound to inhibitors (a) CGP 38′560 (1) and (b) 3.
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the structure of human renin in complex with inhibitor 1,
for example. Instead, water molecules have been located
in S3sp [18,20]).
Aromatic and aliphatic amino acid sidechains form the
surface of the S3sp sub-pocket. Purely hydrophobic sub-
stituents attached to the inhibitor P3 moiety such as the
benzyl group of inhibitor 6 can therefore be accommo-
dated in S3sp (Figure 6c). This is in contrast to the pro-
posal of Tong et al. [20] who described this pocket as
being more polar than the S3-binding site. For inhibitors
7–10, in addition to hydrophobic contacts, a hydrogen-
bond interaction is observed between the distal oxygen of
the inhibitor’s ether sidechain and the amide nitrogen of
Tyr14 (Table 3). The ether oxygen occupies the same
position as the oxygen atom of the water molecule in the
complex of human renin and CGP 38′560 (1; water mol-
ecule 370 in PDB entry 1rne). Our structure–activity
studies [36–38] have shown that this hydrogen-bond inter-
action via the terminal ether group contributes only mod-
erately to the in vitro binding of such inhibitors. This
oxygen atom can be replaced by a hydrophobic –CH2–
group leading to in vitro equipotent inhibitors within the
different series, possibly due to reduced desolvation
energy as compared to the ether analogues. Interestingly,
no major conformational changes of the amino acid
sidechains flanking the S3sp channel, nor its overall size,
were observed between the apo-enzyme structure and the
different enzyme–inhibitor complexes.
The carboxylic ester residue at the P3 heterocycle of
inhibitor 3 complexed to the enzyme was oriented perpen-
dicular to the axis of the binding cleft, with the termi-
nal–CH3 directed towards the open S3sp pocket. The ester
carbonyl of 3 forms hydrogen bonds with both the back-
bone amide nitrogen and the Oγ atom of Ser219 (Table 3).
The orientation and hydrogen-bond pattern of the
enzyme-bound inhibitor through its methyl carboxylate, as
discovered by the X-ray analysis, was not anticipated by
the initial molecular modelling studies that led to the
design of the topological inhibitor 3. Subsequently, in vivo
highly potent analogues such as compounds 4 and 5
resulted from replacing the P3sp ester group of 3 by
residues that would penetrate more deeply into the S3sp
site and that are also more stable towards potential meta-
bolic degradation [29]. Similarly, the proximal P3sp ether
oxygen of inhibitors 7–9 is found in a remote position to
the entrance of the S3sp subsite and hence are not within
binding distance of Ser219 in the enzyme-bound crystal
structures as was suggested from modelling [35]. However,
in the crystal structure with inhibitor 10, a water molecule
is observed at the entrance of the S3sp pocket, which forms
bridging hydrogen bonds with the proximal ether oxygen
of the inhibitor P3sp side chain (3 Å) and the hydroxyl
group of Ser219 (2.8 Å). The P3 methoxy ether oxygen
atom in inhibitor 10 is involved in a hydrogen-bond
network through a water molecule with the hydroxyl group
of Thr12 and other water molecules in the P3 pocket.
The topological inhibitors of the new series lack the P2–P4
peptide backbone, the S2 and the S4 pockets are unoccu-
pied and consequently the corresponding extensive hydro-
gen-bonding network observed in the peptide mimicking,
type-I inhibitors [25] is missing (Figure 7). In general, the
protein structure in this region of the active site is
unchanged in both peptide and nonpeptide inhibitor com-
plexes. There is, however, one exception: the sidechain of
His287 has a different orientation in the structures with
peptide inhibitors of renin (e.g. CGP 38′560, 1). Here, the
sidechain of His287 forms a water-mediated hydrogen
bond with the amide nitrogen atoms of both residues 219
and 220 and the carbonyl P3 of the inhibitor. In contrast,
the His287 imidazole ring in the structures containing non-
peptidic inhibitors is rotated about its χ1 angle by 150°
thus forming a hydrophobic contact with Tyr220
(Figure 6d). The same observation was made by Tong
et al. [20] in the analysis of their polyhydroxymonoamide
complexes where His287 was found to be in the same con-
formation as in the structures of renin with nonpeptidic
inhibitors presented here. The lack of the P2–P4 portion
of the new inhibitors is partly compensated for by the
increased hydrophobic van der Waals contacts within the
contiguous S1 and S3 pockets and their large hydrophobic
surface, as seen in all crystal complexes of the novel
inhibitors, and as reported by others [33,34]. For example,
inhibitors 3–5 have affinities to human renin that are more
than 50 times stronger than compound 2 (Table 1). We
have predicted that mimicking the conserved P3–P2 car-
bonyl interaction of type-I inhibitors to Ser219 of renin
would be important for the proper positioning of the new
topological inhibitors within the extended substrate-
binding cleft [35]. Also, we assumed that penetration of
the P3sp sidechain into the distinct S3sp channel, being
flanked at its entrance by Ser219 and oriented perpendicu-
lar to the axis of the enzyme cavity, would help to tightly
anchor the inhibitor molecule in a favourable position
along the cleft relative to the catalytic aspartates, probably
before closing of the flap domain upon the ligand. Indeed,
the additional hydrophobic and/or hydrogen-bonding
interactions to the S3sp sub-pocket or to the Ser219
sidechain hydroxyl group (as in the case of 3, 10) are essen-
tial for the strong in vitro affinity of such inhibitors with
IC50 values in the low nanomolar range. The extrusion of
several water molecules from the mixed polar–hydropho-
bic S3sp pocket of the apo-enzyme upon inhibitor binding
is obviously entropically/enthalpically favoured, even if
the inhibitor bears a highly hydrophobic P3sp residue. In
addition, the fact that the number of bound water mol-
ecules varies depending on the structure of the complexed
type-I inhibitor [18,20] also indicates less tightly bound
water molecules within the cavity, in agreement with its
partly hydrophobic character.
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Protein crystallography has been an integral part of our
drug discovery program directed towards the design of a
new generation of orally active renin inhibitors. The avail-
ability of the three-dimensional structures of several novel
nonpeptide inhibitors of different compound series in
complex with human renin has provided important and
unexpected insight into the binding interactions of such
inhibitors, and was thus the basis for a more efficient opti-
misation of the initial potent lead structures. First, all the
inhibitors examined were indeed shown to have a large
van der Waals surface interaction with the hydrophobic
contiguous S3–S1 binding pocket. These results provided
direct experimental evidence for the validity of our origi-
nal design concept based on a computer modelling
hypothesis of tethering an extended hydrophobic
(P3–P1)-moiety to a classical transition-state mimetic [30],
as has also been demonstrated by others (the discovery of
novel potent 3,4,5-trisubstituted piperidines and their
X-ray structures in complex with renin have been dis-
closed during the preparation of this manuscript [39]).
Second, the discovery of a distinct channel of human renin
that is accessible from the P3 and is an important nonsub-
strate binding cavity first for inhibitors 3 and 6 triggered
our subsequent medicinal chemistry efforts to focus on
the structural optimisation of the inhibitor P3sp sidechain
to improve the overall inhibitor profile. Third, on the basis
of these findings, new synthetically attractive P3sp–P3
pharmacophores (compounds 7,8) have rapidly evolved
from the iterative design approach [37,38]. 
Our current understanding of the observed remarkably
high enzyme specificity of the reported novel inhibitors
for renin versus related aspartic proteases such as pepsin
(Table 1), cathepsin D and E [37,38] can be rationalised
on the molecular level because only renin possesses the
subsite S3sp. More difficult is explaining the significant
specificity of the compounds for human renin over renin
from some other mammalian species (data not shown).
Comparative protein modelling of dog, rabbit or cat renin
could help to explain the observed specificity for primate
renin as compared to renin of other mammals. The discov-
ery that a water-filled, nonsubstrate pocket that is accessi-
ble from the enzyme substrate-binding cleft can serve as
an additional or alternative binding site for highly potent
topological inhibitors may have general implications for
the future design of novel type-III inhibitors of related
aspartic acid proteases or proteases of other families of
therapeutic interest. 
Significance
Inhibiting renin to treat hypertension appears to be
attractive because of the high specificity and unique role
of this enzyme in the renin–angiotensin cascade. Renin
is known to exclusively catalyse the cleavage reaction
that produces angiotensin I from angiotensinogen. Renin
inhibitors are therefore expected to avoid the adverse
side effects sometimes observed with compounds that
interfere with other proteins of this cascade, (e.g.
angiotensin-converting enzyme, ACE). In clinical trials
several type I (peptide-like) renin inhibitors reduced high
blood pressure in patients with similar pharmacological
efficacy as compared to ACE inhibitors [22]. All potent
renin inhibitors investigated to date, however, show
insufficient oral bioavailability or short duration of
action requiring high oral dosing, and therefore are
unlikely to be useful as therapeutic agents.
The concerted effort using molecular modelling tech-
niques, crystallographic structure elucidation and biologi-
cal assays has led to the design of novel, highly potent
and selective nonpeptide inhibitors of human renin.
These small-molecule inhibitors have favourable physic-
ochemical properties, such as remarkably good water
solubility and low lipophilicity as compared to type-I
inhibitors, and are resistant to rapid biodegradation by
peptidases in the intestinal tract, blood circulation and
liver. Several of these compounds including 4, 5 [29] and
7–10 [36–38] showed good oral absorption in marmoset
monkeys (see the Materials and methods section).
Inhibitor 10, which has sub-nanomolar binding affinity
and is highly specific for human renin has pronounced
in vivo activity in primates after oral administration. It
has been selected as a candidate for clinical trials and is
presently under clinical investigation by Speedel Pharma
AG, Basel.
Materials and methods
Renin and inhibitors
Prorenin was cloned and expressed in Chinese hamster ovary cells,
purified by affinity chromatography using a monoclonal antibody and
activated using immobilised trypsin as previously described [40] to
obtain recombinant glycosylated human renin. Synthesis of inhibitors
7–10 has been reported in preliminary communications [36–38]. The
synthesis of the other nonpeptide inhibitors mentioned here will be dis-
closed in due course. In vitro potencies of compounds against purified
human recombinant renin were determined as described in [26].
Crystallography
Crystals of recombinant glycosylated human renin were grown as
described in Lim et al. [41]. The crystals belong to the space group
P213 with a = b = c = ~143.0 Å. There are two molecules of renin per
asymmetric unit. These crystals were used for inhibitor soaking experi-
ments. Inhibitor-enzyme cocrystallisation experiments (inhibitor 7) pro-
vided tetragonal crystals belonging to space group P41212 with
a = b = 98.4 and c = 95.6 Å [18]. For inhibitor 10, recombinant glyco-
sylated human renin was cocrystallised with the inhibitor in 0.6 M
ammonium acetate, 12% (w/v) PEG 4000 and 0.1 M sodium citrate
buffer pH 3.0. The crystals obtained were cubic and belong to space
group P213 with two molecules in the asymmetric unit and
a = b = c = 141.6 Å. For soaking experiments (inhibitors 3, 6, 8 and 9),
a crystal of renin was soaked into a glass capillary with a small amount
of the reservoir solution and a small amount of the inhibitor was sus-
pended into the solvent close to the crystal. After 30 min to 1 h the
solution was removed from the crystals for data collection.
X-ray diffraction data were collected using a FAST area detector (Delft
Instruments, The Netherlands) positioned on a FR571 rotating anode
X-ray generator (Delft Instruments) operated at 40 kV and 70 mA pro-
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ducing CuKα graphite monochromated radiation and having an apparent
focal spot of 0.3 × 0.3 mm2. The crystal-to-detector distance was 80 mm
for the cubic crystals and 60 mm for the tetragonal crystal. The detector
was positioned at a swing-out angle of 15°. Frames of 0.1° were col-
lected; the exposure time was 2 min per frame. The frames were
processed by the program MADNES [42] the measured data were
processed and merged using the CCP4 program suite [43].
X-ray diffraction data for the inhibitor 10–renin complex crystals were
collected at 100 K using a MAR image plate mounted on a FR 591
rotating anode generator (Enraf-Nonius) operating at 4.1 kW and pro-
ducing graphite monochromated CuKα radiation. 81 frames were col-
lected (exposure: 3 passes of 10 min each, crystal rotation: 0.5° per
frame). The data were processed and scaled using the MARXDS and
the MARSCALE software programs [44]. Data collection and statistics
are summarised in Table 2.
The structures were determined by applying difference Fourier
methods, using the models previously obtained for both tetragonal and
cubic crystals [18]. Although the cubic crystal form contains two mol-
ecules in the asymmetric unit, they were refined separately and no mol-
ecular averaging was applied because it has been observed previously
that the two molecules are in different conformations, an ‘open’ and
‘closed’ form. The inhibitors were positioned in the active site by super-
position on Fobs–Fcalc maps. The structures were then refined using
programs TNT [45] or XPLOR [46] (Table 2). Manual rebuilding of the
models was performed with the program O [47]. For the complex with
10, all reflections were used and a solvent correction was applied. A
free Rfactor of 0.266 was obtained for this complex.
In vivo studies
Oral administration of the novel inhibitors to conscious, unrestrained
(telemetered) and Na+-depleted marmosets [48] resulted in a pro-
nounced long lasting (up to 24 h) and dose dependent (1–10 mg/kg
p.o.) reduction of mean arterial pressure (MAP) paralleled by complete
inhibition of plasma renin activity in vivo. ∆MAPmax = 25–30 mmHg was
observed during the first 4 h (3 mg/kg dose) for compound 10.
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